United States

FFO (TTM)

FFO/share (TTM)

FFO/share Guidance

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Total Portfolio Occupancy

Retail is evolving, and we are here to lead. We intend to profit from the dislocation in retail real estate by investing in and redeveloping mispriced and misunderstood assets. SITE Centers seeks to produce compelling, sustainable results for stakeholders through creative and active management of retail real estate.

SITE Centers

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, SITC is classified as investment grade

Period: 2022 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 3/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2022 Q4

Years since IPO: 15/15,
FFO Growth: 13/15,
FFO/share Growth: 3/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 13/15,
FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 12/15
            

Period: 2025 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 12/15
            

Period: 2025 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 12/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology's immunotherapy platforms PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the National Cancer Institute (NCI) will present new clinical data at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in National Harbor, Maryland.

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allianz Asset Management GmbH lowered its holdings in shares of Site Centers Corp. (NYSE: SITC) by 61.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,792 shares of the company's stock after selling 49,817 shares during the quarter. Allianz Asset Management

Allianz Asset Management GmbH Sells 49,817 Shares of Site Centers Corp. $SITC

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers' Third Quarter 2025 Earnings to be Released Wednesday, November 5, 2025.

SITE Centers' Third Quarter 2025 Earnings to be Released Wednesday, November 5, 2025

Site Centers Corp. (NYSE: SITC - Get Free Report) has received an average recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The

Site Centers Corp. (NYSE:SITC) Receives Consensus Recommendation of “Hold” from Brokerages

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers, today announced a special cash distribution on its common shares of $1.00 per common share payable on November 14, 2025 to shareholders of record at the close of business on October 31, 2025. About SITE Centers Corp. SITE Centers is an owner and manager of open-air shopping centers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company,.

SITE Centers Announces Special Common Stock Distribution

SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial, industry, scientific and medical conferences this fall, providing the opportunity to highlight continued momentum and recent developments among a broad range of stakeholder audiences. These conferences include: 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 - Metropolitan Club, New York City, New York Aptevo will participate in a panel on Acute Myeloid Leukemia titled "Novel AML Therapies Showing Clear Clinical Progress," discussing progress and recent trial outcomes of its lead asset, mipletamig, and sharing emerging evidence of its differentiated clinical profile in frontline AML-where strong safety, tolerability, and early efficacy continue to demonstrate meaningful potential for improved patient outcomes Biotechnology Innovation Organization (BIO)-Europe 2025 - 31st Annual International Partnering Conference November 3-5, 2025 (in-person); Digital Partnering Days: November 11-12, 2025 - Messe Wien Exhibition & Congress Center, Vienna, Austria The Business Development Team will be on-site and actively participating in meetings at the largest biotechnology meeting in Europe Society of Immunotherapy in Cancer (SITC) 2025 - 40th Anniversary Annual Meeting November 5-9, 2025 - Gaylord National Resort & Convention Center, National Harbor, Maryland Aptevo's R&D Team will present a poster highlighting a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive the tumor microenvironment American Society of Hematology (ASH) 2025 - 67th American Society of Hematology Annual Meeting & Exposition December 6-9, 2025 - Orange County Convention Center, Orlando, Florida Interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mip

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company will have three poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, including the first clinical data on the novel CoREST inhibitor TNG260 in non-small cell lung cancer. SITC will be held November 5-9, 2025 in National Harbor, Maryland.

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40 th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD.

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland. The Phase 2 trial evaluated evorpacept, the Company's lead therapeutic candidate, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel, for patients with previously treated HER2-positive advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer.

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows:

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced multiple upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 6-9, 2025 at the Gaylord National Convention Center in National Harbor, Maryland.

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The details are listed below.

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Edgewater Towne Center.

SITE Centers Announces Sale of Edgewater Towne Center

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS' THIRD QUARTER 2025 EARNINGS TO BE RELEASED WEDNESDAY, NOVEMBER 5, 2025.

SITE CENTERS' THIRD QUARTER 2025 EARNINGS TO BE RELEASED WEDNESDAY, NOVEMBER 5, 2025

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS CORP. (NYSE: SITC), AN OWNER OF OPEN-AIR SHOPPING CENTERS, TODAY ANNOUNCED A SPECIAL CASH DISTRIBUTION ON ITS COMMON SHARES OF $1.00 PER COMMON SHARE PAYABLE ON NOVEMBER 14, 2025 TO SHAREHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON OCTOBER 31, 2025. ABOUT SITE CENTERS CORP. SITE CENTERS IS AN OWNER AND MANAGER OF OPEN-AIR SHOPPING CENTERS. THE COMPANY IS A SELF-ADMINISTERED AND SELF-MANAGED REIT OPERATING AS A FULLY INTEGRATED REAL ESTATE COMPANY,.

SITE CENTERS ANNOUNCES SPECIAL COMMON STOCK DISTRIBUTION

SEATTLE, WASHINGTON / ACCESS NEWSWIRE / OCTOBER 8, 2025 / APTEVO THERAPEUTICS ("APTEVO" OR THE "COMPANY") (NASDAQ:APVO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL BISPECIFIC AND TRISPECIFIC IMMUNO-ONCOLOGY THERAPEUTICS, TODAY ANNOUNCED ITS PARTICIPATION IN UPCOMING KEY FINANCIAL, INDUSTRY, SCIENTIFIC AND MEDICAL CONFERENCES THIS FALL, PROVIDING THE OPPORTUNITY TO HIGHLIGHT CONTINUED MOMENTUM AND RECENT DEVELOPMENTS AMONG A BROAD RANGE OF STAKEHOLDER AUDIENCES. THESE CONFERENCES INCLUDE: 4TH ANNUAL ROTH HEALTHCARE OPPORTUNITIES CONFERENCE OCTOBER 9, 2025 - METROPOLITAN CLUB, NEW YORK CITY, NEW YORK APTEVO WILL PARTICIPATE IN A PANEL ON ACUTE MYELOID LEUKEMIA TITLED "NOVEL AML THERAPIES SHOWING CLEAR CLINICAL PROGRESS," DISCUSSING PROGRESS AND RECENT TRIAL OUTCOMES OF ITS LEAD ASSET, MIPLETAMIG, AND SHARING EMERGING EVIDENCE OF ITS DIFFERENTIATED CLINICAL PROFILE IN FRONTLINE AML-WHERE STRONG SAFETY, TOLERABILITY, AND EARLY EFFICACY CONTINUE TO DEMONSTRATE MEANINGFUL POTENTIAL FOR IMPROVED PATIENT OUTCOMES BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)-EUROPE 2025 - 31ST ANNUAL INTERNATIONAL PARTNERING CONFERENCE NOVEMBER 3-5, 2025 (IN-PERSON); DIGITAL PARTNERING DAYS: NOVEMBER 11-12, 2025 - MESSE WIEN EXHIBITION & CONGRESS CENTER, VIENNA, AUSTRIA THE BUSINESS DEVELOPMENT TEAM WILL BE ON-SITE AND ACTIVELY PARTICIPATING IN MEETINGS AT THE LARGEST BIOTECHNOLOGY MEETING IN EUROPE SOCIETY OF IMMUNOTHERAPY IN CANCER (SITC) 2025 - 40TH ANNIVERSARY ANNUAL MEETING NOVEMBER 5-9, 2025 - GAYLORD NATIONAL RESORT & CONVENTION CENTER, NATIONAL HARBOR, MARYLAND APTEVO'S R&D TEAM WILL PRESENT A POSTER HIGHLIGHTING A NOVEL TRISPECIFIC TARGETING NECTIN-4, CD3 AND CD40 TO OVERCOME THE IMMUNOSUPPRESSIVE THE TUMOR MICROENVIRONMENT AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2025 - 67TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING & EXPOSITION DECEMBER 6-9, 2025 - ORANGE COUNTY CONVENTION CENTER, ORLANDO, FLORIDA INTERIM RESULTS FROM THE ONGOING PHASE 1B/2 RAINIER TRIAL EVALUATING MIP

APTEVO PRESENTING SCIENTIFIC AND CLINICAL UPDATES AT SITC AND ASH, ALSO PARTICIPATING IN LEADING FINANCIAL AND INDUSTRY CONFERENCES IN THE FOURTH QUARTER

BOSTON, OCT. 06, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THAT THE COMPANY WILL HAVE THREE POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2025, INCLUDING THE FIRST CLINICAL DATA ON THE NOVEL COREST INHIBITOR TNG260 IN NON-SMALL CELL LUNG CANCER. SITC WILL BE HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

TANGO THERAPEUTICS TO PRESENT FIRST CLINICAL DATA FROM TNG260 AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2025

BOSTON AND LONDON, OCT. 03, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED ITS ABSTRACT HAS BEEN ACCEPTED FOR ORAL PRESENTATION AT THE 40 TH ANNUAL SITC MEETING BEING HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MD.

AKARI THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING

 CHS-114, AN ANTI-CCR8 CYTOLYTIC ANTIBODY, WILL ALSO BE FEATURED IN SITC'S UPCOMING WEBINAR SERIES TARGETS FOR CANCER IO: A DEEP DIVE ON OCTOBER 22, 2025   CHS-114, AN ANTI-CCR8 CYTOLYTIC ANTIBODY, WILL ALSO BE FEATURED IN SITC'S UPCOMING WEBINAR SERIES TARGETS FOR CANCER IO: A DEEP DIVE ON OCTOBER 22, 2025 

COHERUS ONCOLOGY ANNOUNCES POSTER PRESENTATION AT THE 40TH ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

NEEDHAM, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- CANDEL THERAPEUTICS, INC. (CANDEL OR THE COMPANY) (NASDAQ: CADL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MULTIMODAL BIOLOGICAL IMMUNOTHERAPIES TO HELP PATIENTS FIGHT CANCER, TODAY ANNOUNCED THE COMPANY WILL PRESENT INSIGHTS FROM ITS ENLIGHTEN DISCOVERY PLATFORM, AND ADDITIONAL DATA FROM THE CAN-2409 (AGLATIMAGENE BESADENOVEC) PROGRAM IN NON-SMALL CELL LUNG CANCER (NSCLC), THROUGH TWO ACCEPTED POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNIVERSARY ANNUAL MEETING, TAKING PLACE NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

CANDEL THERAPEUTICS TO PRESENT AT THE SITC 2025 ANNUAL MEETING

SOUTH SAN FRANCISCO, CALIF., OCT. 03, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED UPDATED DATA FROM ITS PHASE 2 ASPEN-06 (NCT05002127) TRIAL WILL BE PRESENTED DURING A POSTER SESSION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING TAKING PLACE NOVEMBER 59, 2025, IN NATIONAL HARBOR, MARYLAND. THE PHASE 2 TRIAL EVALUATED EVORPACEPT, THE COMPANY'S LEAD THERAPEUTIC CANDIDATE, IN COMBINATION WITH HERCEPTIN(TRASTUZUMAB), CYRAMZA(RAMUCIRUMAB) AND PACLITAXEL, FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE ADVANCED GASTRIC CANCER (GC) AND GASTROESOPHAGEAL JUNCTION (GEJ) CANCER.

ALX ONCOLOGY TO PRESENT UPDATED DATA FROM PHASE 2 ASPEN-06 TRIAL, HIGHLIGHTING CD47 EXPRESSION AS A PREDICTIVE BIOMARKER IN HER2+ GASTRIC CANCER, AT 40TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

WATERTOWN, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THAT THREE POSTERS WILL BE PRESENTED AT THE UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING, TAKING PLACE NOVEMBER 5-9, 2025, IN NATIONAL HARBOR, MARYLAND. DETAILS FOR THE POSTER PRESENTATIONS ARE AS FOLLOWS:

WEREWOLF THERAPEUTICS TO PRESENT POSTERS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING

WALTHAM, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED MULTIPLE UPCOMING POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING, TAKING PLACE FROM NOVEMBER 6-9, 2025 AT THE GAYLORD NATIONAL CONVENTION CENTER IN NATIONAL HARBOR, MARYLAND.

XILIO THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING

PHILADELPHIA AND VANCOUVER, BRITISH COLUMBIA, OCT. 03, 2025 (GLOBE NEWSWIRE) -- BRIACELL THERAPEUTICS CORP. (NASDAQ: BCTX, BCTXW, BCTXZ) (TSX: BCT) (BRIACELL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY THAT DEVELOPS NOVEL IMMUNOTHERAPIES TO TRANSFORM CANCER CARE, IS PLEASED TO ANNOUNCE THAT THE COMPANY WILL BE PRESENTING PRECLINICAL BRIA-OTS+ DATA AT A POSTER PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNIVERSARY ANNUAL MEETING, HELD NOVEMBER 7-9, 2025, IN NATIONAL HARBOR, MD. THE DETAILS ARE LISTED BELOW.

BRIACELL TO PRESENT BRIA-OTS+ PRECLINICAL DATA AT SITC 2025 ANNUAL MEETING

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS ANNOUNCES SALE OF EDGEWATER TOWNE CENTER.

SITE Centers

SITC

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

SITC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

SITC